Solid Tumor
Conditions
Brief summary
Open-label, non-randomized, Phase I, dose-escalating, first-in-man study.
Detailed description
The study consisted of a screening period, a treatment period with repeated 28-day treatment cycles (duration treatment with ICP-105), and a follow-up period (within 30 days of the last dose and post-treatment follow-up 30 days after the last visit). The recruited patients receive a single dose on day 1, then after a 3-day washout period, multiple dosing will be initiated following dose-escalation schedule. The dose-limiting toxicity (DLT) assessment period consisted of Cycle 0 (single dose and washout period) and Cycle 1 (28-day cycle).
Interventions
DRUGICP-105
25mg, 100mg capsule
Sponsors
Beijing InnoCare Pharma Tech Co., Ltd.
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 Years and older. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1. * At least one evaluable disease according to RECIST1.1. * Histologically or cytologically confirmed solid tumors, failure to respond to standard therapy, or for whom standard therapy does not exist. * Adequate bone marrow, liver, renal, and cardiovascular function.
Exclusion criteria
* Previous treatment with FGF19, FGFR4 inhibitors and/or pan-FGFR inhibitors. * Anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal, targeted therapy, or investigational agents within four weeks of the first dose of ICP-105. * Major surgery within 6 weeks of the first dose of ICP-105. * Significant GI disorder(s) that could interfere with the absorption, metabolism, or excretion of ICP-105. * Crohn's disease with symptoms and systemic treatment. * Central nervous system (CNS) metastasis. * Current clinically significant cardiovascular disease including: * Any class 3 or 4 cardiac disease such as arrhythmia, congestive heart failure or myocardial infarction defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction (LVEF) \< 50%, Primary cardiomyopathy, clinical significant QTc prolong history or QTc\>470ms (female) QTc\>450ms (male). * Known active bleeding within 2 months of screening or 6 months of bleeding history. * Lung function impairment by pleural effusion or ascites, any history of interstitial pneumonia, deep vein thrombosis, pulmonary embolism. * Known active infection with HBV, HCV or HIV or any uncontrolled active systemic infection. * Non-hematological toxicity must recover to ≤ Grade 1 from prior anti-cancer therapy (excluding alopecia, nausea and vomiting). * Lactating or pregnant women, or women who will not use contraception during the study and for 180 days after the last dose of study drug if sexually active and able to bear children.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Every cycle (28 days) for approximately 24 months or earlier if patient terminates from the study | will be evaluated by CTCAE v4.03 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cmax | Every cycle (28 days) for approximately 24 months or earlier if patient terminates from the study | the peak plasma concentration |
| AUC | Every cycle (28 days) for approximately 24 months or earlier if patient terminates from the study | area under the plasma concentration vs. time curve |
| Apparent half-life for designated elimination phases (t½) | Every cycle (28 days) for approximately 24 months or earlier if patient terminates from the study | will be measured and calculated with noncompartmental analysis using WinNonlin |
Countries
China
Outcome results
None listed